Dark

ARWR
Arrowhead Research Corporation
stock NASDAQ

At Close

Jul 17, 2026 3:59:56 PM EDT

74.33USD+4.140%(+2.96)3,775,226

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 17, 2026 8:53:30 AM EDT

70.31USD-1.492%(-1.07)1,100

After-hours

Jul 17, 2026 4:04:30 PM EDT

74.40USD+0.094%(+0.07)1,647,642

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

06:23AM EST SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Raises Price Target to $46 Benzinga

Jan 19, 2022

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 Benzinga

08:24AM EST Goldman Sachs Upgrades Arrowhead Pharmaceuticals to Buy Benzinga

Jan 12, 2022

07:33AM EST Arrowhead Pharma Initiates Phase 3 PALISADE Study Of ARO-APOC3 For Treatment Of Familial Chylomicronemia Syndrome RTTNews

07:30AM EST Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study Of ARO-APOC3 For Treatment of Familial Chylomicronemia Syndrome Benzinga

Dec 11, 2021

08:21AM EST ARWR: License Agreement with GSK for ARO-HSD Benzinga

Dec 9, 2021

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Nov 23, 2021

08:10AM EST The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug Benzinga

07:14AM EST GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead Benzinga

05:48AM EST SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Raises Price Target to $45 Benzinga

Nov 22, 2021

04:02PM EST Arrowhead Pharmaceuticals FY21 EPS $(1.36), Down From $(0.84) YoY Benzinga

04:02PM EST Arrowhead Pharmaceuticals Enters Exclusive License Agreement With GSK For ARO-HSD; Arrowhead To Receive $120M Upfront Payment For Phase 1/2 Program For NASH Benzinga

03:54AM EST Earnings Scheduled For November 22, 2021 Benzinga

Nov 21, 2021

03:05PM EST The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week Benzinga

Nov 19, 2021

11:26AM EST Earnings Outlook For Arrowhead Pharmaceuticals Benzinga

Nov 18, 2021

09:47AM EST Arrowhead Pharmaceuticals Option Alert: Jan 21 $80 Calls at the Ask: 68 @ $5.0 vs 1075 OI; Earnings 11/22 After Close Ref=$71.13 Benzinga

Nov 17, 2021

09:08AM EST Arrowhead Announces JNJ-75220795 In Development For NASH Benzinga

Nov 15, 2021

01:01PM EST Arrowhead Pharmaceuticals Collaborator Presents Phase 2b Clinical Data From REEF-1 Study In Patients With Chronic Hepatitis B Infection Benzinga

11:00AM EST Arrowhead Presents New Clinical Data On ARO-APOC3 At AHA 2021 Benzinga

Nov 12, 2021

07:43AM EST Arrowhead Presents Additional Clinical Data On Investigational ARO-HSD Treatment At AASLD Liver Meeting Benzinga

Oct 25, 2021

07:34AM EDT Arrowhead Pharmaceuticals Announced it Filed for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases Business Wire - Oct 25 07:30 EDT Benzinga

Sep 30, 2021

07:31AM EDT Arrowhead Pharmaceuticals Initiates Phase 2b Study Of ARO-APOC3 For Treatment of Mixed Dyslipidemia Benzinga

Sep 28, 2021

07:36AM EDT Arrowhead Earns $10M Phase 1 Milestone Payment Benzinga

Aug 10, 2021

06:02AM EDT HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $100 Benzinga

Aug 6, 2021

09:35AM EDT Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $94 Benzinga

Aug 5, 2021

05:29PM EDT Recap: Arrowhead Pharmaceuticals Q3 Earnings Benzinga

04:00PM EDT Arrowhead Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $45.89M Beat $37.52M Estimate Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 29, 2021

07:35AM EDT Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation From FDA For ARO-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency Associated Liver Disease Benzinga

Jul 6, 2021

05:36PM EDT Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright Benzinga

10:39AM EDT Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer Benzinga

07:31AM EDT Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Benzinga

Jul 2, 2021

02:46PM EDT Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher Benzinga

12:18PM EDT Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet Benzinga

10:28AM EDT Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 850,000 Jobs In June Benzinga

10:05AM EDT Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) tanked nearly 20% on Friday morning after the drug company said it has paused a mid-stage study of ARO-ENaC, the company's investigational treatment for patients with cystic fibrosis. RTTNews

08:20AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Jul. 2, 2021: ADP, DIDI, CRNC, ARWR, LEVI Benzinga

07:31AM EDT UPDATE: Arrowhead Says Pause Related To 'a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation' Benzinga

07:30AM EDT Arrowhead Pharma Reports Pauses Its ARO-ENaC Phase 1/2 Trial Benzinga

Jun 30, 2021

07:35AM EDT Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia Benzinga

Jun 28, 2021

09:56AM EDT Arrowhead Pharma Early Saturday Highlighted Presentation Of Added Interim 48-Week Liver Biopsy Results From Ongoing Study For Its Investigational RNA Interference Therapeutic Being Co-Developed With Takeda Benzinga

Jun 25, 2021

07:31AM EDT Arrowhead Highlights Presentation Of Preclinical Data On ARO-DUX4 At FSHD Society International Research Congress Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 23, 2021

07:33AM EDT Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress Benzinga

Jun 21, 2021

11:36AM EDT Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate Benzinga

07:38AM EDT Arrowhead Pharma, Horizon Therapeutics Announce Global Collaboration And License Agreement For ARO-XDH RTTNews

07:31AM EDT Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout; Arrowhead To Receive $40M Upfront Benzinga

07:30AM EDT Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout Business Wire

Jun 3, 2021

07:35AM EDT Arrowhead Pharma Initiates Phase 2b Study Of Investigational ARO-APOC3 For Treatment Of Severe Hypertriglyceridemia RTTNews

07:31AM EDT Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia Benzinga

May 18, 2021

09:10AM EDT Arrowhead Receives $10M Option Exercise Fee From Janssen Benzinga

May 6, 2021

11:21AM EDT ARWR: Catalyst-Rich Summer Upcoming Benzinga

May 4, 2021

04:00PM EDT Arrowhead Pharmaceuticals Q2 EPS $(0.26) Misses $(0.13) Estimate, Sales $32.81M Miss $37.70M Estimate Benzinga

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 28, 2021

11:47AM EDT Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease Benzinga

08:04AM EDT Arrowhead Pharmaceuticals Announces Improvement In Fibrosis After ARO-AAT Treatment In Patients With Alpha-1 Liver Disease Benzinga

Apr 15, 2021

07:34AM EDT Arrowhead Announces ARO-DUX4 As First Muscle Targeted RNAi Candidate Using TRiMTM Platform Benzinga

Mar 1, 2021

07:32AM EST Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia Benzinga

Feb 8, 2021

11:55AM EST B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $106 Benzinga

Feb 5, 2021

11:34AM EST Piper Sandler Maintains Overweight on Arrowhead Pharmaceuticals, Raises Price Target to $99 Benzinga

10:14AM EST Arrowhead Pharmaceuticals shares were trading lower after the company reported worse-than-expected Q1 EPS results and reported Q1 sales results were lower year over year. Benzinga

09:27AM EST HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $95 Benzinga

08:45AM EST Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $97 Benzinga

Feb 4, 2021

05:31PM EST Arrowhead Pharmaceuticals: Q1 Earnings Insights Benzinga

04:01PM EST Arrowhead Pharmaceuticals Q1 EPS $(0.20) Misses $0.17 Estimate, Sales $21.30M Down From $29.45M YoY Benzinga

08:35AM EST Earnings Scheduled For February 4, 2021 Benzinga

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Jan 28, 2021

11:25AM EST Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). GlobeNewswire Inc

Jan 25, 2021

07:37AM EST Arrowhead Pharmaceuticals Files IND For Phase 2b Study Of ARO-ANG3 For Treatment Of Mixed Dyslipidemia Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 21, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 21, 2020 Benzinga

06:32AM EST Baird Downgrades Arrowhead Pharmaceuticals to Neutral Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 7, 2020

04:10PM EST Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4) Benzinga

Dec 2, 2020

08:00AM EST NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. GlobeNewswire Inc

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

04:13AM EST SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Lowers Price Target to $34 Benzinga

Nov 23, 2020

05:22PM EST Recap: Arrowhead Pharmaceuticals Q4 Earnings Benzinga

04:01PM EST Arrowhead Pharmaceuticals FY20 EPS $(0.84) Down From $0.69 YoY, Sales $87.00 Down From $168.80M YoY Benzinga

04:05AM EST Earnings Scheduled For November 23, 2020 Benzinga

Nov 19, 2020

09:41AM EST Benzinga's Top Upgrades, Downgrades For November 19, 2020 Benzinga

07:46AM EST Citigroup Initiates Coverage On Arrowhead Pharmaceuticals with Buy Rating, Announces Price Target of $90 Benzinga

Nov 13, 2020

09:07AM EST Arrowhead Pharma Reports Interim Clinical Data Showed ARO-AAT Treatment Improve Multiple Biomarkers Of Alpha-1 Liver Disease Benzinga

Nov 4, 2020

07:42AM EST Arrowhead Pharmaceuticals To Host Key Opinion Leader Webinars On Cardiometabolic Candidates ARO-APOC3 And ARO-ANG3 Nov. 18 And Nov. 19 Benzinga

Oct 15, 2020

02:51PM EDT Why Arrowhead Pharmaceuticals Is Trading Higher Today Benzinga

10:24AM EDT Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed Benzinga

Oct 14, 2020

05:19PM EDT 13 Stocks Moving In Wednesday's After-Hours Session Benzinga

Oct 8, 2020

08:16AM EDT Japan's Takeda Pharmaceutical Co. Ltd. (TAK) and Arrowhead Pharmaceuticals Inc. (ARWR) said Thursday they have entered into a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). RTTNews

07:36AM EDT Takeda And Arrowhead Collaborate To Co-Develop And Co-Commercialize ARO-AAT For Alpha-1 Antitrypsin-Associated Liver Disease Benzinga

07:35AM EDT Takeda And Arrowhead Announce Collaboration, Licensing Agreement To Develop ARO-AAT RTTNews

07:30AM EDT Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease Business Wire

Sep 27, 2020

02:03AM EDT ARWR: Better Than Anticipated Interim Data for Benzinga

Sep 24, 2020

04:31PM EDT Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Marketplace Rule 5635(c)(4) Benzinga

Sep 22, 2020

08:08AM EDT Cramer Weighs In On Diamondpeak, Caesars Entertainment And More Benzinga

Sep 17, 2020

08:25AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

06:20AM EDT SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Raises Price Target to $31 Benzinga

Sep 16, 2020

02:36PM EDT Mid-Afternoon Market Update: Dow Jumps 300 Points; Fed Leaves Interest Rates Unchanged Benzinga

12:01PM EDT Mid-Day Market Update: Crude Oil Surges 4%; Eastman Kodak Shares Spike Higher Benzinga

10:23AM EDT Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed Benzinga

10:19AM EDT Mid-Morning Market Update: Markets Open Higher; FedEx Tops Q1 Expectations Benzinga

09:58AM EDT Shares of Arrowhead Pharmaceuticals Inc. (ARWR) are currently gaining over 25% on Wednesday morning after the company reported positive interim results from a mid-stage trial of treatment for rare genetic liver disease. RTTNews

07:35AM EDT Arrowhead Announces ARO-AAT Phase 2 Interim Results Benzinga

Aug 31, 2020

05:43AM EDT Arrowhead Presenting Positive New Phase 1/2 Clinical Data Monday on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 Benzinga

Aug 30, 2020

08:24AM EDT The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga

Aug 28, 2020

07:33AM EDT Arrowhead And Collaborator Janssen Highlights Presentation Of Phase 2 Clinical Data On Investigational Hepatitis B Therapeutic JNJ-3989 At The Digital Liver Congress Benzinga

Aug 18, 2020

07:34AM EDT Arrowhead Pharmaceuticals Initiates Phase 1b Study Of ARO-HIF2 For Treatment Of Clear Cell Renal Cell Carcinoma Benzinga

Aug 11, 2020

07:34AM EDT Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study Of ARO-ENaC For Treatment Of Cystic Fibrosis Benzinga

Aug 5, 2020

04:01PM EDT Arrowhead Pharmaceuticals Q3 EPS $(0.13) Misses $(0.12) Estimate, Sales $27.38M Miss $28.91M Estimate Benzinga

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 29, 2020

11:58AM EDT Arrowhead Pharmaceuticals shares are trading higher after the company announced it has earned a $20 million milestone payment from Amgen for the start of a Phase 2 trial of AMG 890. Benzinga

07:40AM EDT Arrowhead Pharmaceuticals Earns $20M Milestone Payment From Amgen For Start Of Phase 2 Trial Of AMG 890 Benzinga